SoC

Phase 2

Pfizer

SoC is one of 93 therapeutic programs targeting Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Small Cell Lung CancerActive, not recruiting

Solid TumorRecruiting

Triple Negative Breast Cancer (TNBC), Early SettingRecruiting

Diabetic Foot Ulcer (DFU)Recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)Recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Solid TumorPreclinical

Recruiting

Triple Negative Breast Cancer (TNBC), Early SettingPhase 2

Recruiting

Diabetic Foot Ulcer (DFU)Preclinical

Recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)Preclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

SoC

Pfizer

Phase 2

1 2

Fludara

Sanofi

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Tulmimetostat

Novartis

Preclinical

1 8

Carboplatin AUC-5

Merck & Co.

Preclinical

1 9

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 10

IN10018

IInxMed (Shanghai) Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Small Cell Lung Cancer

NCT05957510

Q1 2027

Phase 2Recruiting

Uncomplicated Plasmodium Falciparum Malaria

NCT07811908

Q3 2027

PreclinicalRecruiting

Diabetic Foot Ulcer (DFU)

NCT07096934

Phase 1Not yet recruiting

Urinary Tract Infections

NCT07371429

Q1 2028

PreclinicalRecruiting

Systemic Sclerosis

NCT07295847

ApprovedNot yet recruiting

Bronchitis

NCT07873632

Clinical

Trials by Indication[1]

COVID-193 trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

Terminated·EEdesa Biotech Inc.·Preclinical·NCT04401475·278 enrolled

Preliminary Clinical Study of Efficacy and Safety of Flunotinib Maleate Tablets Combined With Antiviral Therapy in Patients With Severe Novel Coronavirus (COVID-19) Infection

Terminated·CChengdu Zenitar Biomedical Technology Co., Ltd·Preclinical·NCT05713279·13 enrolled

Real World Evaluation of COVID-19 Burden and Nirmatrelvir/Ritonavir in Taiwan Using National Health Insurance Research Database

Completed· Pfizer logo

Pfizer··NCT06085924·2,315,187 enrolled

Uncomplicated Plasmodium Falciparum Malaria2 trials

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria

Recruiting· Novartis logo

Novartis·Phase 2·NCT07811908·120 enrolled

Completed· Novartis logo

Novartis·Phase 2·NCT07811882·95 enrolled

Systemic Sclerosis1 trial

A Phase 1b/2, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07295847·27 enrolled

Acute Coronary Syndrome1 trial

Comparative, Randomized, Multicenter, Followed by an Open Label Extension Trial in Patients With a Recent Acute Coronary Syndrome Evaluating the Early Inclusion of Inclisiran Into Standard of Care Versus Standard of Care Alone in Kingdom of Saudi Arabia

Not yet recruiting· Novartis logo

Novartis·Approved·NCT07684469·300 enrolled

Bronchitis1 trial

A Randomized, Dosing vs Standard of Care, Single-Center, Multiple Dose Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion

Not yet recruiting·UUniversity of North Carolina, Chapel Hill·Approved·NCT07873632·40 enrolled

9 more indications

Solid Tumor1 trial

A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Recruiting·AArvinas Inc.·Preclinical·NCT07749586·499 enrolled

AML1 trial

A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)

Active, not recruiting·TTScan Therapeutics, Inc.·Phase 1·NCT05473910·310 enrolled

Urinary Tract Infections1 trial

Phase 1, Open-Label, Single Arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants From 2 to Less Than 12 Years of Age With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis With Antibiotics

Not yet recruiting· GSK logo

GSK·Phase 1·NCT07371429·25 enrolled

Breast Cancer1 trial

TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE-BDT)

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT07340541·700 enrolled

AML - Acute Myeloid Leukemia1 trial

A Phase 1 Multicenter Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

Withdrawn·BBlueSphere Bio, Inc·Phase 1·NCT07566585

Diabetic Foot Ulcer (DFU)1 trial

A Prospective, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care

Recruiting·FFibroBiologics·Preclinical·NCT07096934·120 enrolled

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Recruiting·UUnknown Sponsor·Preclinical·NCT05985655·230 enrolled

Triple Negative Breast Cancer (TNBC), Early Setting1 trial

The LESLIE Trial: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Systemic Therapy in Patients With Triple Negative Breast Cancer

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT06831955·356 enrolled

Small Cell Lung Cancer1 trial

Evaluation of Safety and Efficacy of Serplulimab Plus Chemotherapy in Patients With Histological Transformation From EGFR-mutated NSCLC to SCLC After Treatment: a Single-arm, Multicenter, Open-label Phase II Study

Active, not recruiting·GGuangdong Association of Clinical Trials·Phase 2·NCT05957510·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for SoC. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SoC. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Pfizer

SoC

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q1 2028

Trials by Indication[1]

COVID-193 trials

Uncomplicated Plasmodium Falciparum Malaria2 trials

Systemic Sclerosis1 trial

Acute Coronary Syndrome1 trial

Bronchitis1 trial

Solid Tumor1 trial

AML1 trial

Urinary Tract Infections1 trial

Breast Cancer1 trial

AML - Acute Myeloid Leukemia1 trial

Diabetic Foot Ulcer (DFU)1 trial

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

Triple Negative Breast Cancer (TNBC), Early Setting1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News